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Alleles of the a1 immunoglobulin gene 39 enhancer control occur in association with various systemic pathologies,
evolution of IgA nephropathy toward renal failure. IgAN, the so-called Berger’s disease, stands as an idio-
Background. IgA nephropathy is the most common glomer- pathic nephropathy. It is the most common nephropathyular disease. Mechanisms leading to its occurrence and con-
worldwide, and especially affects white people and mostlytrolling the evolution of the disease remain largely unknown.
males [1]. The initial features are often mild, with hema-Various genetic factors have been found, mostly implicating
immunologically relevant genes (IgH, TCR, human lympho- turia and proteinuria, usually after an infectious episode.
cyte antigen, and complement loci). A regulatory region recently Diagnosis can also be suggested later on, at the time of
identified downstream, the a1 gene of the IgH locus, was a hypertension, edemas, or renal failure. Although initiallylikely candidate for the control of IgA1 production in patients.
considered as benign, it is now clear that the diseaseAlleles of this region, differing by size, sequence, and orienta-
frequently leads to renal failure. Factors for a poor prog-tion of the a1 hs1,2 transcriptional enhancer, were first identi-
fied through Southern blot hybridization. nosis are hypertension, microhematuria, renal failure at
Methods. We established a polymerase chain reaction (PCR) the stage of diagnosis, elevated proteinuria (.3 g/day),
method suitable for routine testing that amplifies minisatellites
and pathologic alterations of the mesangium [2]. What-within the a1 hs1,2 enhancer, with variable numbers of tandem
ever the stage, diagnosis relies on a kidney biopsy thatrepeats (VNTR) defining the two alleles. This assay allowed
the typing of 104 patients with IgAN and 83 healthy volunteers. shows IgA deposits associated with complement (mainly
Results from typing of a1 hs1,2 alleles were compared with C3 or C4) or other immunoglobulins (IgG or IgM).
long-term clinical outcome in patients. Enhancer alleles were The pathophysiology of mesangial deposits involves
compared in a luciferase reporter gene assay.
immunologic mechanisms that are not elucidated; they mayResults. The a1 hs1,2 alleles do not constitute a predictive
rely on both qualitative and quantitative changes in IgAfactor for IgA nephropathy, since similar allelic frequencies
were observed in healthy individuals and in unrelated Euro- production. Negatively charged and poorly glycosylated
pean patients. In contrast, among patients, homozygosity for IgA may become able to bind positively charged colla-
the weakest enhancer allele (AA genotype) was significantly cor- gen, fibronectin, or the membrane of mesangial cells [2–4].related with a milder form of the disease, whereas the allele
Specific antigens have been suggested to elicit an abnor-B was associated with severe evolution. The minisatellite region
mal immune response skewed toward the synthesis ofwithin the a1 hs1,2 enhancer carried potential transcription
factor-binding sites, and its duplication increased the transcrip- IgA1. Such a skewed response may yield circulating im-
tional strength of the a1 hs1,2 allele B over that of allele A. mune complexes comprised of antigens, IgA, occasion-
Conclusion. Altogether, these alleles may constitute a risk ally IgG, and complement, ultimately forming patho-factor for the prognosis of IgA nephropathy.
genic deposits in the kidney.
Familial predisposition has been documented [5, 6],
but the inheritance of the disease has not been firmlyIgA nephropathy (IgAN) is defined by IgA deposits in
associated with specific genes. Many factors seem to in-the kidney mesangium. Although secondary IgA deposits
fluence the outcome of IgAN, such as human lymphocyte
antigen (HLA) haplotypes [7–9], the level of HLA ex-
pression on natural killer (NK) lymphocytes [10], the C4Key words: glomerular disease, risk for IgAN, Berger’s disease, mesan-
gial deposits, progressive kidney disease. null complement factor phenotype, allelic forms of the
angiotensin-converting enzyme [11, 12], or the genes forReceived for publication August 28, 1999
an IgA-specific glycosyl transferase [13–15].and in revised form February 11, 2000
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pensity to a high expression of the IgH a gene or of Patients with renal failure. Sixty-four patients had cre-
atininemia levels above 150 mmol/L or a deteriorationcytokines that promote switching toward IgA has been
suggested [16, 17]. Sm and Sa switch regions of the IgH of clearance over 3 mL/min/year as determined by the
Cockroft formula [25, 26], and dialysis or kidney trans-locus, and transcription of the Ia region is a key element
of class switching to IgA. Their role in the pathophysiol- plantation was necessary in 42 of them (65%). The mean
duration of follow-up in this group before the occurrenceogy of IgAN is controversial: Specific allelic forms have
been found to be associated with a more severe evolution of renal failure was 7.25 6 0.87 years.
Patients without renal failure. This group of 40 patientsof IgAN in two studies [18, 19], but not in a third one
[20]. Meanwhile, Ia1 germline transcripts have been re- had creatininemia values below 150 mmol/L at the begin-
ning of the study (mean follow-up 8.3 6 0.9 years).ported to be absent in IgAN patients by one group [21],
whereas they were increased and their promoter fre- Whole blood cell DNA was prepared from all 104
patients and from 83 healthy volunteers of the Limogesquently carried specific mutations in a study of Japanese
patients [17]. area, with no history of renal disease. Our control popu-
lation included 27 men and 56 women ages 21 to 55 yearsIn an attempt to find new genetic markers and to
understand better the molecular basis of IgAN, we fo- old (mean 40.20 6 0.89 years old).
cused on the polymorphism of a region lying downstream
Polymerase chain reactionthe a1 gene. This region contains three enhancers, hs3,
hs1,2, and hs4, and is homologous to the murine 39 IgH DNA was digested overnight with proteinase K (1 mg/
mL), phenol and chloroform extracted, alcohol precipi-palindromic locus control region [22–24]. By Southern
blot we previously identified a restriction fragment length tated, and adjusted to a concentration of 1 mg/mL in Tris
10 mmol/L, EDTA 0.1 mol/L.polymorphism of that region, with at least two different
alleles (a1a and a1b) [22]. These alleles differ by the DNA fragments including the VNTR region of the
hs1,2 enhancer were amplified with consensus primersorientation of the hs1,2 element and by inclusion of vari-
able numbers of tandem repeats (VNTR): The a1a hs1,2 flanking the 53 bp repeats in both a1A and a1B (Fig. 1):
primer 1, 59-GGGTCCTGGTCCCAAAGATGGC-39allele has one 53 bp repeat, and the a1b allele carries
two; meanwhile, the a2 gene has four repeats [22, 23]. (678C); primer 2, 59-TTCCCAGGGGTCCTGTGGGT
CC-39 (698C).Since Southern blotting is tedious work and only indi-
cates the orientation of hs1,2, we have designed a poly- The following sizes were expected for amplification
products: a1B gene, 409 1 (2 3 53) 5 515 bp, and a1Amerase chain reaction (PCR) assay that specifically am-
plifies the VNTR within hs1,2. We named the alleles gene, 409 1 (1 3 53) 5 462 bp.
Reactions were carried out in 30 mL of a mix madedefined by PCR a1A and a1B, by analogy to the nomencla-
ture of Southern blot alleles (a1a and a1b) [22]. The up of dNTP 8 mmol/L, 100 nmol/L of each primer, 1 3
Taq buffer, and 0.2 U Taq Polymerase (Pharmacia, Upp-tandemly repeated minisatellite motif features the pres-
ence of several potential binding sites for transcription sala, Sweden). PCR was performed on a Robocycler
Gradient 96 (Stratagene, La Jolla, CA, USA). DNA wasfactors, including mE1 and nuclear factor-kB (NF-kB)
[22]. We wished to address the hypothesis that the dupli- denaturated three minutes at 948C and then submitted
to 10 cycles that consisted of 948C for 45 seconds, 668Ccated motif in the a1B allele may boost the transcription
of the a1 gene and play a role in the pathophysiology for 55 seconds, and 728C for 45 seconds, followed with
another 20 cycles at 648C for 105 seconds for the anneal-of IgAN. The distribution of PCR alleles was thus deter-
mined in healthy individuals as well as in patients suffer- ing step. A final elongation step was realized at 728C for
10 minutes. The product was then analyzed on a 2%ing mild or severe forms of idiopathic IgAN.
agarose gel stained with ethidium bromide; 280 nm ultra-
violet illumination was allowed to score the homozygotes
METHODS
(AA or BB) and heterozygotes patterns (AB; Fig. 1).
Patients
Luciferase assaysAll members of our study group gave their informed
consent, and the study design was in agreement with the A lymphoid-specific vector for reporter gene assays
was constructed by inserting an immunoglobulin heavylocal ethical committee. Blood samples were collected
in ethylenediaminetetraacetic acid (EDTA) vials from chain VH promoter upstream the luciferase gene (Luc)
in the pGL3 vector (Promega Corporation, Madison, WI,104 patients suffering from kidney biopsy-confirmed
IgAN. These Caucasoid patients included 81 men and USA). Fragments containing either one repeat (hs1,2
a1A allele) or two repeats (hs1,2 a1B allele) of the 5323 women, originating from the Limoges, Poitiers, Brive,
and Pe´rigueux areas of France. Ages ranged from 13 to bp minisatellite were first cloned in pCRII-topo cloning
vector (Invitrogen, Groningen, The Netherlands) and69 years old (mean 41.24 6 1.23 years old). Patients were
ranked according to their clinical status: inserted downstream the Luc gene in the pVH promoter-
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Fig. 1. (A) Map of the IgH locus showing the
hs1,2 enhancer downstream from the a1 gene
and also showing the polymerase chain reac-
tion (PCR) amplification. Different orienta-
tion and numbers of tandem repeats in the a1
gene can be seen in the a1A allele (one repeat)
and a1B allele (two repeats). (B) Patterns of
PCR amplification: AB genotype (a1A and a1B
allele fragments), BB genotype (a1B allele
fragment), and AA genotype (a1A allele frag-
ment).
Fig. 2. (A) Construction: hs1,2 elements were cloned as BamH1-Xho1 fragments in BamH1-Sal1 sites of the pGL3-pVH vector. (B) Estimation
of the luciferase activity in the a1A and a1B fragments compared with the VH promoter basal activity (pVH). Results are reported as mean 6
SEM of six samples. One representative experiment out of two is shown. *P 5 0.01 (Mann-Whitney U-test) as compared with a1A.
driven Luc reporter plasmid in their normal respective For transient transfection assay, 5 3 105 U266 human
plasma cells were transfected with equal molar amountsorientations (Fig. 2). An enhancerless construction, in-
cluding only the pVH promoter-driven Luc gene, was (corresponding to 400 ng of pGL3-pVH construct) of each
construct, using Superfect transfection reagent (Qiagentransfected in the same conditions to evaluate basal tran-
scription. Transfection efficiencies were controlled by GmbH). For each assay, 400 ng of pCMV b vector (Clon-
tech) were added as an internal control, and for eachsimultaneous transfection of a control b galactosidase
expression vector (pCMV b vector; Clontech, Palo Alto, construct, six assays were performed in parallel. PGL3
Control vector plasmid (Promega Corp.) was used as aCA, USA). Plasmid DNAs were prepared using plasmid
Maxi Kit (Qiagen GmbH, Hilden, Germany). positive control. After 18 hours, cultures in RPMI 1640
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Table 1. Distribution of the three hs1,2 genotypes among controls and patients
Patients
Patients with renal failure Patients without renal failure Total Control
AA 4 (6.2%) 8 (20%) 12 (11.5%) 13 (15.6%)
BB 30 (46.9%) 10 (25%) 40 (38.5%) 36 (43.4%)
AB 30 (46.9%) 22 (55%) 52 (50%) 34 (41%)
Total 64 40 104 83
Follow-up 7.2560.86 years before 8.360.9 years
kidney failure
Patients were divided according to the progression of the disease. Years of follow-up are indicated.
medium (Life Technologies, Tassin, France) supple- renal failure. The presence of allele A was significantly
associated with stability of the disease and was presentmented with 10% fetal calf serum, 2 mmol/L l-glutamine,
100 mg/mL penicillin, and 10 mg/mL streptomycin, cells in 75% of the 40 patients without renal failure versus
only 53% of the patients with renal failure (x2 5 4.1,were centrifuged and lyzed five minutes at room temper-
ature in 100 mL of lysis buffer (K2HPO4 100 mmol/L, P 5 0.04).
KH2PO4 10 mmol/L, Triton O.2%, dithiothreitol 1
Relationship between rapid or slow evolution andmmol/L). After centrifugation, the supernatant was used
hs1,2 genotypesto assay luciferase activity in the Luclite Plus assay kit
(Packard Bioscience BV, Groningen, The Netherlands) We also wished to consider statistically how fast the
and b galactosidase activity with the luminescent b-gal patients progressed to renal failure. Rather than splitting
detection kit (Clontech) to standardize the assay. The patients in two groups at the time of insertion in the
luminescent assays were all performed in 96-well Op- study, the Kaplan–Meier analysis allowed us to take into
tiplates (Packard Bioscience BV) in a Lumicount mi- account the delay between diagnosis and occurrence or
croplate reader luminometer (Packard Bioscience BV). not of renal failure. This delay was 11.5 6 4.1 years in
B allele-negative patients versus 6.97 6 1.24 years in all
Statistical analysis B allele-positive patients (Fig. 3). The mean time lapse
Statistical analysis was performed with the Statviews after which 25% patients suffered renal failure was 14 6
software (Alsym, Meylan, France). Frequencies were 2.3 years in the B allele-negative group and only in 3 6
compared by the x2 method, Mann-Whitney, or Fisher 2.2 years in the B allele-positive group.
test when appropriate, and were considered significantly
Luciferase assaysdifferent when P values were less than 0.05. The odds
ratios were calculated by the Haldane method [27]. Since the B allele of the hs1,2 a1 enhancer apparently
A dynamic study of the outcome of the disease ac- represented a risk factor for a disease involving increased
cording to genotypes was carried out by considering time IgA1 production, we compared the transcriptional strength
lapses between diagnosis and the occurrence of renal of the various hs1,2 VNTR regions in luciferase gene
failure through a Kaplan–Meier statistical test, and dif- reporter assays. Fragments from the hs1,2 a1A allele man-
ferences in those rates were evaluated by means of log ifested a weaker activity (P 5 0.01, Mann-Whitney U-
rank test. test) than the hs1,2 a1B allele (209.9 6 18.0 vs. 142.3 6
15.9 for the a1B and a1A alleles, respectively; Fig. 2).
RESULTS
DISCUSSIONRelationship between clinical status and
hs1,2 genotypes Although genetic factors obviously play a role in the
occurrence and evolution of idiopathic IgAN, most cor-First we compared the repartition of the different ge-
notypes and alleles between the patients and the control relations reported between the disease and alleles at
specific loci have proven to be weak and are subject topopulation (Table 1). Allelic frequencies did not differ
between the patients and control groups (A allele, 36.5 geographic or ethnical variations. Beside a strong preva-
lence in males, with a sex ratio varying from 2:1 to 6:1,vs. 36.2%; B allele, 63.5 vs. 63.8%), and the distribution
was in agreement with the Hardy–Weinberg equation. depending on the geographic area (with a 3.5:1 ratio in
the present study), several reports have documented theIn contrast, the patients separated into two groups of
either mild or severe clinical evolution appeared to differ influence of alleles mapping within the IgH locus [14,
17, 19, 20].significantly, and the 64 patients with renal failure carried
the B allele more often than the 40 patients without We amplified the different allelic forms of the IgH a1
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Fig. 3. Progression curves toward renal failure estimated by the Kaplan–Meier analysis. The AA genotype confers a protection in IgA nephropathy
patients (P 5 0.04). Symbols in A are: (solid line) allele A1 (N 5 59); (dotted line) allele A– (N 5 37). Symbols in B are: (solid line) allele B1
(N 5 85); (dotted line) allele B– (N 5 11). P values were not significant in A, but P 5 0.01 in B.
gene hs1,2 enhancer by PCR. This PCR identifies two satellite region and to be much more easily done in
alleles for the a1 gene: allele A characterized by a band routine testing than Southern blots, which previously
of 462 bp, and allele B characterized by a band of 515 have been used for the identification of switch region
bp. We found that the allele frequencies in IgAN patients alleles.
did not differ significantly from those defined in the con- Altogether, our results encourage us to think that poly-
trol population. By contrast, allele frequencies signifi- morphism at the IgH 39 regulatory region could play an
cantly differed between patients with either mild or severe important role in the outcome of idiopathic IgAN. The
evolution of the disease. The B allele was significantly presence of the B allele described herein confers a more
more represented in those patients with renal failure, important calculated odds ratio [3.93 (1.13; 13.74)] for
who often required dialysis or kidney transplantation. malign progression than the one conferred by the “refer-
Another remarkable feature appeared when the delay ence” HLA-DQB1*0301 allele [1.64 (0.65; 4.18)] [9]
between diagnosis and occurrence of renal failure was when it is measured in our population of patients with
taken into account for the statistical analysis: The B allele renal failure and patients without renal failure who were
was associated with a fast slope on the progression curve followed for at least four years (data not shown). The
(P 5 0.01; Fig. 3). B allele finally confers a significant risk of severe out-
The a1 gene hs1,2 enhancer contains variable numbers come and rapid evolution. The frequencies of hs1,2 al-
of a 53 bp minisatellite sequence carrying consensus leles and genotypes in normal individuals are such that
binding sites for transcription factors such as NF-kB. their determination has no diagnostic value by itself;
In transcriptional reporter gene assays, the minisatellite however, they could be useful markers for the evaluation
region of the B allele, which contains two repeats, carries of a prognosis, especially in association with other known
a stronger transcriptional enhancer activity than the sin- genetic markers such as HLAs, complement factors, or
gle-repeat allele A. Since the hs1,2 enhancer has been pos-
switch region alleles. Finally, the role of such enhancer
tulated to play an important role in class switching [28],
alleles in the transcriptional control of the a1 gene pro-
a tempting conclusion is that allele B of hs1,2 increases
vides a new clue toward unraveling the complex patho-
switching toward the a1 gene. Allele B could then directly
physiology of IgAN.play a role in the evolution of IgAN by a long-term pro-
motion of a higher rate of IgA1 production through in-
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